

Dennis M Black

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/152383/publications.pdf>

Version: 2024-02-01

168
papers

34,687
citations

6254

80
h-index

4991

167
g-index

170
all docs

170
docs citations

170
times ranked

15586
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. <i>Lancet, The</i> , 1996, 348, 1535-1541. | 13.7 | 3,496 |
| 2 | Risk Factors for Hip Fracture in White Women. <i>New England Journal of Medicine</i> , 1995, 332, 767-773. | 27.0 | 3,296 |
| 3 | Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2007, 356, 1809-1822. | 27.0 | 2,536 |
| 4 | Effects of Continuing or Stopping Alendronate After 5 Years of Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2927. | 7.4 | 1,208 |
| 5 | The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2003, 349, 1207-1215. | 27.0 | 1,133 |
| 6 | Postmenopausal Osteoporosis. <i>New England Journal of Medicine</i> , 2016, 374, 254-262. | 27.0 | 1,101 |
| 7 | Fracture Risk Reduction with Alendronate in Women with Osteoporosis: The Fracture Intervention Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 4118-4124. | 3.6 | 877 |
| 8 | Prevalent Vertebral Deformities Predict Hip Fractures and New Vertebral Deformities but Not Wrist Fractures. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 821-828. | 2.8 | 693 |
| 9 | Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. <i>American Journal of Medicine</i> , 2002, 112, 281-289. | 1.5 | 679 |
| 10 | Clinical Use of Bone Densitometry. <i>JAMA - Journal of the American Medical Association</i> , 2002, 288, 1889. | 7.4 | 664 |
| 11 | Interim Report and Recommendations of the World Health Organization Task-Force for Osteoporosis. <i>Osteoporosis International</i> , 1999, 10, 259-264. | 3.1 | 634 |
| 12 | Simple measurement of femoral geometry predicts hip fracture: The study of osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , 1993, 8, 1211-1217. | 2.8 | 606 |
| 13 | One Year of Alendronate after One Year of Parathyroid Hormone (1 μ g/84) for Osteoporosis. <i>New England Journal of Medicine</i> , 2005, 353, 555-565. | 27.0 | 568 |
| 14 | Association of BMD and FRAX Score With Risk of Fracture in Older Adults With Type 2 Diabetes. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 2184. | 7.4 | 561 |
| 15 | Comparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. <i>Journal of Bone and Mineral Research</i> , 1996, 11, 984-996. | 2.8 | 558 |
| 16 | The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 243-254. | 2.8 | 552 |
| 17 | Hip Fracture in Women without Osteoporosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2005, 90, 2787-2793. | 3.6 | 542 |
| 18 | Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 1595-1622. | 3.6 | 470 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Bisphosphonates and Fractures of the Subtrochanteric or Diaphyseal Femur. <i>New England Journal of Medicine</i> , 2010, 362, 1761-1771. | 27.0 | 456 |
| 20 | Axial and appendicular bone density predict fractures in older women. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 633-638. | 2.8 | 447 |
| 21 | Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy. <i>Journal of Bone and Mineral Research</i> , 2002, 17, 1-10. | 2.8 | 437 |
| 22 | Contribution of vertebral deformities to chronic back pain and disability. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 449-456. | 2.8 | 435 |
| 23 | An Assessment Tool for Predicting Fracture Risk in Postmenopausal Women. <i>Osteoporosis International</i> , 2001, 12, 519-528. | 3.1 | 415 |
| 24 | II. Meta-Analysis of Alendronate for the Treatment of Postmenopausal Women. <i>Endocrine Reviews</i> , 2002, 23, 508-516. | 20.1 | 396 |
| 25 | Prevalent Vertebral Deformities Predict Mortality and Hospitalization in Older Women with Low Bone Mass. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 241-249. | 2.6 | 395 |
| 26 | Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1250-1258. | 2.8 | 357 |
| 27 | Effects of Hormone Therapy on Cognition and Mood in Recently Postmenopausal Women: Findings from the Randomized, Controlled KEEPSâ€œCognitive and Affective Study. <i>PLoS Medicine</i> , 2015, 12, e1001833. | 8.4 | 330 |
| 28 | Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the study of osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 1778-1787. | 2.8 | 327 |
| 29 | Age-related decrements in bone mineral density in women over 65. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 625-632. | 2.8 | 317 |
| 30 | Pentosidine and Increased Fracture Risk in Older Adults with Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 2380-2386. | 3.6 | 281 |
| 31 | Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1246-1254. | 6.7 | 276 |
| 32 | Arterial Imaging Outcomes and Cardiovascular Risk Factors in Recently Menopausal Women. <i>Annals of Internal Medicine</i> , 2014, 161, 249. | 3.9 | 274 |
| 33 | Continuing Bisphosphonate Treatment for Osteoporosis â€œ For Whom and for How Long?. <i>New England Journal of Medicine</i> , 2012, 366, 2051-2053. | 27.0 | 249 |
| 34 | Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX Trial. <i>Journal of Bone and Mineral Research</i> , 2010, 25, 976-982. | 2.8 | 241 |
| 35 | Randomized Trial of Effect of Alendronate Continuation Versus Discontinuation in Women With Low BMD: Results From the Fracture Intervention Trial Long-Term Extension. <i>Journal of Bone and Mineral Research</i> , 2004, 19, 1259-1269. | 2.8 | 238 |
| 36 | A new approach to defining normal vertebral dimensions. <i>Journal of Bone and Mineral Research</i> , 1991, 6, 883-892. | 2.8 | 233 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Alendronate and Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2007, 356, 1895-1896. | 27.0 | 228 |
| 38 | Comparison of methods for defining prevalent vertebral deformities: The study of osteoporotic fractures. <i>Journal of Bone and Mineral Research</i> , 1995, 10, 890-902. | 2.8 | 226 |
| 39 | Fracture risk in diabetic elderly men: the MrOS study. <i>Diabetologia</i> , 2014, 57, 2057-2065. | 6.3 | 215 |
| 40 | The Effect of 6 versus 9 Years of Zoledronic Acid Treatment in Osteoporosis: A Randomized Second Extension to the HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2015, 30, 934-944. | 2.8 | 205 |
| 41 | Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. <i>New England Journal of Medicine</i> , 2020, 383, 743-753. | 27.0 | 201 |
| 42 | Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 632-642. | 2.8 | 197 |
| 43 | Femoral Bone Strength and Its Relation to Cortical and Trabecular Changes After Treatment With PTH, Alendronate, and Their Combination as Assessed by Finite Element Analysis of Quantitative CT Scans. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1974-1982. | 2.8 | 191 |
| 44 | Proximal Femoral Structure and the Prediction of Hip Fracture in Men: A Large Prospective Study Using QCT. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1326-1333. | 2.8 | 178 |
| 45 | Prediction of new clinical vertebral fractures in elderly men using finite element analysis of CT scans. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 808-816. | 2.8 | 169 |
| 46 | Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of Raloxifene Evaluation trial ¹¹ Eli Lilly and Company (Indianapolis, IN) sponsored the Multiple Outcomes of Raloxifene Evaluation (MORE) trial.. <i>Bone</i> , 2003, 33, 293-300. | 2.9 | 168 |
| 47 | Risk Factors for a First-Incident Radiographic Vertebral Fracture in Women 65 Years of Age: The Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 131-140. | 2.8 | 167 |
| 48 | Defining Incident Vertebral Deformity: A Prospective Comparison of Several Approaches. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 90-101. | 2.8 | 166 |
| 49 | Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial. <i>Journal of Bone and Mineral Research</i> , 2005, 21, 292-299. | 2.8 | 163 |
| 50 | Recovery of Function After Hip Fracture The Role of Social Supports. <i>Journal of the American Geriatrics Society</i> , 1988, 36, 801-806. | 2.6 | 154 |
| 51 | Biochemical Markers of Bone Turnover and Prediction of Hip Bone Loss in Older Women: The Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 1999, 14, 1404-1410. | 2.8 | 151 |
| 52 | Hormonal Predictors of Bone Loss in Elderly Women: A Prospective Study. <i>Journal of Bone and Mineral Research</i> , 1998, 13, 1167-1174. | 2.8 | 150 |
| 53 | Incidence and demography of femur fractures with and without atypical features. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 977-986. | 2.8 | 147 |
| 54 | Establishing a Reference Interval for Bone Turnover Markers in 637 Healthy, Young, Premenopausal Women From the United Kingdom, France, Belgium, and the United States. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 389-397. | 2.8 | 143 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. <i>Endocrine Reviews</i> , 2019, 40, 333-368. | 20.1 | 136 |
| 56 | Appendicular bone mineral and a woman's lifetime risk of hip fracture. <i>Journal of Bone and Mineral Research</i> , 1992, 7, 639-646. | 2.8 | 131 |
| 57 | Intestinal Calcium Absorption Decreases Dramatically After Gastric Bypass Surgery Despite Optimization of Vitamin D Status. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 1377-1385. | 2.8 | 131 |
| 58 | Goal-Directed Treatment for Osteoporosis: A Progress Report From the ASBMR-NOF Working Group on Goal-Directed Treatment for Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 3-10. | 2.8 | 127 |
| 59 | Correlates of Kyphosis in Older Women. <i>Journal of the American Geriatrics Society</i> , 1997, 45, 682-687. | 2.6 | 122 |
| 60 | Efficacy and Safety of a Once-€Yearly Intravenous Zoledronic Acid 5âmg for Fracture Prevention in Elderly Postmenopausal Women with Osteoporosis Aged 75 and Older. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 292-299. | 2.6 | 121 |
| 61 | Risk Factors for a First-Incident Radiographic Vertebral Fracture in Women â65 Years of Age: The Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 131-140. | 2.8 | 120 |
| 62 | Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2020, 8, 672-682. | 11.4 | 117 |
| 63 | Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy. <i>JAMA Internal Medicine</i> , 2014, 174, 1126. | 5.1 | 116 |
| 64 | Teriparatide, Vitamin D, and Calcium Healed Bilateral Subtrochanteric Stress Fractures in a Postmenopausal Woman with a 13-Year History of Continuous Alendronate Therapy. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1627-1632. | 3.6 | 109 |
| 65 | Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: The HORIZON-Pivotal Fracture Trial (PFT). <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1627-1634. | 2.8 | 109 |
| 66 | Effects of antiresorptive therapies on glucose metabolism: Results from the FIT, HORIZON-PFT, and FREEDOM trials. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 1348-1354. | 2.8 | 109 |
| 67 | Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4546-4554. | 3.6 | 109 |
| 68 | Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis. <i>Mayo Clinic Proceedings</i> , 2017, 92, 200-210. | 3.0 | 109 |
| 69 | Effects of Yearly Zoledronic Acid 5 mg on Bone Turnover Markers and Relation of PINP With Fracture Reduction in Postmenopausal Women With Osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2009, 24, 1544-1551. | 2.8 | 108 |
| 70 | Effect of Alendronate on Vertebral Fracture Risk in Women With Bone Mineral Density T Scores of â1.6 to â2.5 at the Femoral Neck: The Fracture Intervention Trial. <i>Mayo Clinic Proceedings</i> , 2005, 80, 343-349. | 3.0 | 99 |
| 71 | The Incidence of Osteonecrosis of the Jaw in Patients Receiving 5 Milligrams of Zoledronic Acid. <i>Journal of the American Dental Association</i> , 2010, 141, 1365-1370. | 1.5 | 99 |
| 72 | The Kronos Early Estrogen Prevention Study (KEEPS). <i>Menopause</i> , 2019, 26, 1071-1084. | 2.0 | 97 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Effect of Once-Yearly Zoledronic Acid Five Milligrams on Fracture Risk and Change in Femoral Neck Bone Mineral Density. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009, 94, 3215-3225. | 3.6 | 96 |
| 74 | Change in Undercarboxylated Osteocalcin Is Associated with Changes in Body Weight, Fat Mass, and Adiponectin: Parathyroid Hormone (1-84) or Alendronate Therapy in Postmenopausal Women with Osteoporosis (the PaTH Study). <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, E1982-E1989. | 3.6 | 95 |
| 75 | Insulin-like Growth Factor 1 and Functional Status in Healthy Older Men. <i>Journal of the American Geriatrics Society</i> , 1995, 43, 1350-1355. | 2.6 | 92 |
| 76 | Prevalent Vertebral Fractures in Black Women and White Women. <i>Journal of Bone and Mineral Research</i> , 2008, 23, 1458-1467. | 2.8 | 90 |
| 77 | Vertebral Fracture Prevalence Among Women Screened for the Fracture Intervention Trial and a Simple Clinical Tool to Screen for Undiagnosed Vertebral Fractures. <i>Mayo Clinic Proceedings</i> , 2000, 75, 888-896. | 3.0 | 89 |
| 78 | Pins and Plaster Aren't Enough: A Call for the Evaluation and Treatment of Patients with Osteoporotic Fractures. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 3482-3486. | 3.6 | 89 |
| 79 | Effect of Alendronate on the Age-Specific Incidence of Symptomatic Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2005, 20, 971-976. | 2.8 | 86 |
| 80 | Bone material properties in actively bone-forming trabeculae in postmenopausal women with osteoporosis after three years of treatment with once-yearly Zoledronic acid. <i>Journal of Bone and Mineral Research</i> , 2011, 26, 12-18. | 2.8 | 82 |
| 81 | Osteoporosis and Hip Fracture Risk From Routine Computed Tomography Scans: The Fracture, Osteoporosis, and CT Utilization Study (FOCUS). <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1291-1301. | 2.8 | 77 |
| 82 | Effects of Abaloparatide-SC on Fractures and Bone Mineral Density in Subgroups of Postmenopausal Women With Osteoporosis and Varying Baseline Risk Factors. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 17-23. | 2.8 | 75 |
| 83 | Effects of Gastric Bypass Surgery on Bone Mass and Microarchitecture Occur Early and Particularly Impact Postmenopausal Women. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 975-986. | 2.8 | 71 |
| 84 | Randomized Trial of Late Surfactant Treatment in Ventilated Preterm Infants Receiving Inhaled Nitric Oxide. <i>Journal of Pediatrics</i> , 2016, 168, 23-29.e4. | 1.8 | 68 |
| 85 | The Ability of a Single BMD and Fracture History Assessment to Predict Fracture Over 25 Years in Postmenopausal Women: The Study of Osteoporotic Fractures. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 389-395. | 2.8 | 68 |
| 86 | Early Cumulative Supplemental Oxygen Predicts Bronchopulmonary Dysplasia in High Risk Extremely Low Gestational Age Newborns. <i>Journal of Pediatrics</i> , 2016, 177, 97-102.e2. | 1.8 | 65 |
| 87 | Overlapping Surgery in the Ambulatory Orthopaedic Setting. <i>Journal of Bone and Joint Surgery - Series A</i> , 2016, 98, 1859-1867. | 3.0 | 62 |
| 88 | Vertebral Fracture Risk in Diabetic Elderly Men: The MrOS Study. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 63-69. | 2.8 | 61 |
| 89 | Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause. <i>JAMA Internal Medicine</i> , 2017, 177, 1471. | 5.1 | 59 |
| 90 | Bone Marrow Fat Changes After Gastric Bypass Surgery Are Associated With Loss of Bone Mass. <i>Journal of Bone and Mineral Research</i> , 2017, 32, 2239-2247. | 2.8 | 59 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | Effect of Insulin Resistance on BMD and Fracture Risk in Older Adults. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3303-3310. | 3.6 | 58 |
| 92 | A Normative Reference Database Study for Pronosco X-posure Systemâ„¢. Journal of Clinical Densitometry, 2001, 4, 5-12. | 1.2 | 57 |
| 93 | Alendronate Reduces the Risk of Multiple Symptomatic Fractures: Results from the Fracture Intervention Trial. Journal of the American Geriatrics Society, 2002, 50, 409-415. | 2.6 | 55 |
| 94 | Risk Factors for Subtrochanteric and Diaphyseal Fractures: The Study of Osteoporotic Fractures. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 659-667. | 3.6 | 53 |
| 95 | Effect of Bisphosphonate Use on Risk of Postmenopausal Breast Cancer. JAMA Internal Medicine, 2014, 174, 1550. | 5.1 | 51 |
| 96 | Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. Journal of Bone and Mineral Research, 2018, 33, 634-642. | 2.8 | 51 |
| 97 | Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Current Medical Research and Opinion, 2009, 25, 921-928. | 1.9 | 50 |
| 98 | BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. Journal of Bone and Mineral Research, 2013, 28, 1319-1327. | 2.8 | 50 |
| 99 | Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling. Journal of Clinical Endocrinology and Metabolism, 2008, 93, 2166-2172. | 3.6 | 48 |
| 100 | Predicting Hip Fracture Type With Cortical Bone Mapping (CBM) in the Osteoporotic Fractures in Men (MrOS) Study. Journal of Bone and Mineral Research, 2015, 30, 2067-2077. | 2.8 | 48 |
| 101 | The relationship between bisphosphonate adherence and fracture: Is it the behavior or the medication? Results from the placebo arm of the fracture intervention trial. Journal of Bone and Mineral Research, 2011, 26, 683-688. | 2.8 | 45 |
| 102 | Epidemiology of Fractures and Assessment of Fracture Risk. Clinics in Laboratory Medicine, 2000, 20, 439-454. | 1.4 | 44 |
| 103 | What Proportion of Incident Radiographic Vertebral Fractures in Older Men Is Clinically Diagnosed and Vice Versa: A Prospective Study. Journal of Bone and Mineral Research, 2016, 31, 1500-1503. | 2.8 | 44 |
| 104 | Six Months of Parathyroid Hormone (1-84) Administered Concurrently versus Sequentially with Monthly Ibandronate Over Two Years: The PTH and Ibandronate Combination Study (PICS) Randomized Trial. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 3522-3529. | 3.6 | 43 |
| 105 | Effects of antiresorptive treatment on nonvertebral fracture outcomes. Journal of Bone and Mineral Research, 2011, 26, 2411-2418. | 2.8 | 40 |
| 106 | Zoledronate. Bone, 2020, 137, 115390. | 2.9 | 39 |
| 107 | High hip fracture risk in men with severe aortic calcification: MrOS study. Journal of Bone and Mineral Research, 2014, 29, 968-975. | 2.8 | 38 |
| 108 | Height loss in older women: Risk of hip fracture and mortality independent of vertebral fractures. Journal of Bone and Mineral Research, 2012, 27, 153-159. | 2.8 | 37 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Prevalence of ABO Maternal-Infant Incompatibility in Asians, Blacks, Hispanics and Caucasians. Vox Sanguinis, 1988, 54, 181-183. | 1.5 | 32 |
| 110 | Predictors of new and severe vertebral fractures: results from the HORIZON Pivotal Fracture Trial. Osteoporosis International, 2012, 23, 53-58. | 3.1 | 30 |
| 111 | Estimating the Time to Benefit for Preventive Drugs with the Statistical Process Control Method: An Example with Alendronate. Drugs and Aging, 2016, 33, 347-353. | 2.7 | 30 |
| 112 | History of alendronate. Bone, 2020, 137, 115411. | 2.9 | 30 |
| 113 | Effects of PTH and Alendronate on Type I Collagen Isomerization in Postmenopausal Women With Osteoporosis: The PaTH Study. Journal of Bone and Mineral Research, 2008, 23, 1442-1448. | 2.8 | 28 |
| 114 | Once-yearly zoledronic acid and days of disability, bed rest, and back pain: Randomized, controlled HORIZON Pivotal Fracture Trial. Journal of Bone and Mineral Research, 2011, 26, 984-992. | 2.8 | 27 |
| 115 | Vitamin D Supplementation and Increased Risk of Falling. JAMA Internal Medicine, 2016, 176, 171. | 5.1 | 27 |
| 116 | Elevations in Serum and Urinary Calcium with Parathyroid Hormone (1-84) with and without Alendronate for Osteoporosis. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 942-947. | 3.6 | 26 |
| 117 | Abdominal aortic calcification and risk of fracture among older women – The SOF study. Bone, 2015, 81, 16-23. | 2.9 | 26 |
| 118 | The KEEPS-Cognitive and Affective Study: Baseline Associations between Vascular Risk Factors and Cognition. Journal of Alzheimer's Disease, 2014, 40, 331-341. | 2.6 | 25 |
| 119 | The Randomized, Controlled Trial of Late Surfactant: Effects on Respiratory Outcomes at 1-Year Corrected Age. Journal of Pediatrics, 2017, 183, 19-25.e2. | 1.8 | 25 |
| 120 | Potential Usefulness of BMD and Bone Turnover Monitoring of Zoledronic Acid Therapy Among Women With Osteoporosis: Secondary Analysis of Randomized Controlled Trial Data. Journal of Bone and Mineral Research, 2016, 31, 1767-1773. | 2.8 | 24 |
| 121 | Bone Turnover Markers Do Not Predict Fracture Risk in Type 2 Diabetes. Journal of Bone and Mineral Research, 2020, 35, 2363-2371. | 2.8 | 24 |
| 122 | Are Women with Thicker Cortices in the Femoral Shaft at Higher Risk of Subtrochanteric/Diaphyseal Fractures? The Study of Osteoporotic Fractures. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 2414-2422. | 3.6 | 23 |
| 123 | Pharmacogenomics of estrogens on changes in carotid artery intima-medial thickness and coronary arterial calcification: Kronos Early Estrogen Prevention Study. Physiological Genomics, 2016, 48, 33-41. | 2.3 | 23 |
| 124 | Degree of Trauma Differs for Major Osteoporotic Fracture Events in Older Men Versus Older Women. Journal of Bone and Mineral Research, 2016, 31, 204-207. | 2.8 | 23 |
| 125 | Prevalence of osteoporosis in the Italian population and main risk factors: results of BoneTour Campaign. BMC Musculoskeletal Disorders, 2016, 17, 396. | 1.9 | 23 |
| 126 | Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIIH-ASBMR SABRE Project. Journal of Bone and Mineral Research, 2020, 37, 29-35. | 2.8 | 23 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 127 | Inclusion of Older Women in Randomized Clinical Trials: Factors Associated with Taking Study Medication in the Fracture Intervention Trial. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 1126-1131. | 2.6 | 22 |
| 128 | Comparison of BMD Changes and Bone Formation Marker Levels 3 Years After Bisphosphonate Discontinuation: FLEX and HORIZON-PFT Extension I Trials. <i>Journal of Bone and Mineral Research</i> , 2019, 34, 810-816. | 2.8 | 22 |
| 129 | Relationship Between Pretreatment Rate of Bone Loss and Bone Density Response to Once-Yearly ZOL: HORIZON-PFT Extension Study. <i>Journal of Bone and Mineral Research</i> , 2015, 30, 570-574. | 2.8 | 21 |
| 130 | Prediction Models of Prevalent Radiographic Vertebral Fractures Among Older Men. <i>Journal of Clinical Densitometry</i> , 2014, 17, 449-457. | 1.2 | 19 |
| 131 | Prediction Models of Prevalent Radiographic Vertebral Fractures Among Older Women. <i>Journal of Clinical Densitometry</i> , 2014, 17, 378-385. | 1.2 | 19 |
| 132 | Association of 3D Geometric Measures Derived From Quantitative Computed Tomography With Hip Fracture Risk in Older Men. <i>Journal of Bone and Mineral Research</i> , 2016, 31, 1550-1558. | 2.8 | 17 |
| 133 | Increases in PYY and uncoupling of bone turnover are associated with loss of bone mass after gastric bypass surgery. <i>Bone</i> , 2020, 131, 115115. | 2.9 | 17 |
| 134 | Bisphosphonates and the risk of atypical femur fractures. <i>Bone</i> , 2022, 156, 116297. | 2.9 | 17 |
| 135 | Health-related quality of life and treatment of postmenopausal osteoporosis: Results from the HORIZON-PFT. <i>Bone</i> , 2011, 48, 1298-1304. | 2.9 | 16 |
| 136 | Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial. <i>Osteoporosis International</i> , 2013, 24, 329-338. | 3.1 | 16 |
| 137 | Time to onset of antifracture efficacy and year-by-year persistence of effect of zoledronic acid in women with osteoporosis. <i>Journal of Bone and Mineral Research</i> , 2012, 27, 1487-1493. | 2.8 | 15 |
| 138 | Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 236-243. | 2.8 | 15 |
| 139 | Maternal Black Race and Persistent Wheezing Illness in Former Extremely Low Gestational Age Newborns: Secondary Analysis of a Randomized Trial. <i>Journal of Pediatrics</i> , 2018, 198, 201-208.e3. | 1.8 | 14 |
| 140 | Epidemiology of fractures and assessment of fracture risk. <i>Clinics in Laboratory Medicine</i> , 2000, 20, 439-53. | 1.4 | 14 |
| 141 | Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. <i>Osteoporosis International</i> , 2013, 24, 1503-1511. | 3.1 | 12 |
| 142 | Inhaled Nitric Oxide Increases Urinary Nitric Oxide Metabolites and Cyclic Guanosine Monophosphate in Premature Infants: Relationship to Pulmonary Outcome. <i>American Journal of Perinatology</i> , 2015, 32, 225-232. | 1.4 | 12 |
| 143 | The Interaction of Acute-Phase Reaction and Efficacy for Osteoporosis After Zoledronic Acid: HORIZON Pivotal Fracture Trial. <i>Journal of Bone and Mineral Research</i> , 2020, 37, 21-28. | 2.8 | 12 |
| 144 | The effects of organic nitrates on osteoporosis: a randomized controlled trial [ISRCTN94484747]. <i>Trials</i> , 2006, 7, 10. | 1.6 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | Low cumulative disease activity is associated with higher bone mineral density in a majority Latinx and Asian US rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 53, 151972. | 3.4 | 11 |
| 146 | The search for the optimal anabolic osteoporosis therapy. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2263-2265. | 2.8 | 10 |
| 147 | A Model of BMD Changes After Alendronate Discontinuation to Guide Postalendronate BMD Monitoring. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 4094-4100. | 3.6 | 10 |
| 148 | Association between femur size and a focal defect of the superior femoral neck. <i>Bone</i> , 2015, 81, 60-66. | 2.9 | 9 |
| 149 | Vignettes in Osteoporosis: A Road Map to Successful Therapeutics. <i>Journal of Bone and Mineral Research</i> , 2003, 19, 3-10. | 2.8 | 7 |
| 150 | Osteoporosis and Bone Biology. , 2016, , 1323-1364. | | 7 |
| 151 | Non-contrast cardiac CT-based quantitative evaluation of epicardial and intra-thoracic fat in healthy, recently menopausal women: Reproducibility data from the Kronos Early Estrogen Prevention Study. <i>Journal of Cardiovascular Computed Tomography</i> , 2020, 14, 55-59. | 1.3 | 7 |
| 152 | A Prospective Open-Label Observational Study of a Buffered Soluble 70mg Alendronate Effervescent Tablet on Upper Gastrointestinal Safety and Medication Errors: The <sc>GastroPASS</sc> Study. <i>JBMR Plus</i> , 2021, 5, e10510. | 2.7 | 7 |
| 153 | Resources in Geriatric Drug Research. <i>Drug Information Journal</i> , 1985, 19, 421-427. | 0.5 | 6 |
| 154 | Consistency of Bone Turnover Marker and Calcium Responses to Parathyroid Hormone (1-84) Therapy in Postmenopausal Osteoporosis. <i>Journal of Clinical Densitometry</i> , 2011, 14, 68-73. | 1.2 | 6 |
| 155 | A Distributed Data Processing System for a Multicenter Clinical Trial. <i>Drug Information Journal</i> , 1986, 20, 83-92. | 0.5 | 5 |
| 156 | Is risedronate or alendronate more effective at preventing nonvertebral fractures in women with osteoporosis?. <i>Nature Clinical Practice Rheumatology</i> , 2007, 3, 378-379. | 3.2 | 5 |
| 157 | A novel effervescent formulation of oral weekly alendronate (70mg) improves persistence compared to alendronate tablets in post-menopausal women with osteoporosis. <i>Aging Clinical and Experimental Research</i> , 2021, 33, 2529-2537. | 2.9 | 5 |
| 158 | Outcomes post fragility fracture among members of an integrated healthcare organization. <i>Osteoporosis International</i> , 2021, , 1. | 3.1 | 5 |
| 159 | Hospitalizations in Pediatric and Adult Patients for All Cancer Type in Italy: The EPIKIT Study under the E.U. COHEIRS Project on Environment and Health. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 495. | 2.6 | 4 |
| 160 | A drinkable formulation of alendronate: potential to increase compliance and decrease upper GI irritation. <i>Clinical Cases in Mineral and Bone Metabolism</i> , 2013, 10, 187-90. | 1.0 | 4 |
| 161 | Prebiotic to Improve Calcium Absorption in Postmenopausal Women After Gastric Bypass: A Randomized Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 1053-1064. | 3.6 | 4 |
| 162 | Reply to: Indications of Increased Vertebral Fracture Risk in Patients With Type 2 Diabetes. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 183-183. | 2.8 | 2 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 163 | Reply to: Change in Bone Density and Reduction in Fracture Risk: A Meta-Regression of Published Trials. Journal of Bone and Mineral Research, 2019, 34, 1977-1978. | 2.8 | 2 |
| 164 | A Perspective on Postmenopausal Bone Loss with Aging. Journal of Bone and Mineral Research, 2020, 37, 171-172. | 2.8 | 2 |
| 165 | Use of Alendronate After 5 Years of Treatmentâ€”Reply. JAMA - Journal of the American Medical Association, 2007, 297, 1979. | 7.4 | 1 |
| 166 | Defining a “Reference Population” No Easy Task. Journal of Bone and Mineral Research, 2009, 24, 1639-1639. | 2.8 | 1 |
| 167 | Bone mineral density as a surrogate biomarker for fracture risk reduction â€” Authors' reply. Lancet Diabetes and Endocrinology, 2020, 8, 876. | 11.4 | 1 |
| 168 | Now That You Can Get What You Want, Can You Keep What You Need?. Journal of Bone and Mineral Research, 2020, 35, 217-218. | 2.8 | 0 |